BCL2 and acute lymphoblastic leukemia: The BCP-ALL cell lines were very sensitive to venetoclax, a selective BCL2 inhibitor, while the T-ALL cell lines were sensitive to BCL2L1 selective inhibitors A-1155463 and A-1331852 (Fig. 5e).